Delving into the Latest Updates on WE011 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Shanghai Baolong Pharmaceutical Co., Ltd.

Active Organization

Shanghai Baolong Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要研究目的：剂量递增阶段： 1) 评价注射用 WE011 在晚期实体瘤患者中的安全性和耐受性； 2) 确定注射用 WE011 的最大耐受剂量（Maximum Tolerated Dose，MTD）。剂量扩展阶段：进一步确定注射用 WE011 在晚期实体瘤（包括但不限于乳腺癌和卵巢癌）患者中的安全性。次要研究目的：剂量递增阶段： 1) 评价注射用 WE011 在晚期实体瘤患者中的药代动力学特征； 2) 初步评价注射用 WE011 在晚期实体瘤患者中的抗肿瘤疗效。剂量扩展阶段： 1) 评价注射用 WE011 在晚期实体瘤患者中的初步有效性； 2) 推荐 II 期剂量。

[Translation]

Primary study objectives: Dose escalation phase: 1) Evaluate the safety and tolerability of WE011 for injection in patients with advanced solid tumors; 2) Determine the maximum tolerated dose (MTD) of WE011 for injection. Dose expansion phase: Further determine the safety of WE011 for injection in patients with advanced solid tumors (including but not limited to breast cancer and ovarian cancer). Secondary study objectives: Dose escalation phase: 1) Evaluate the pharmacokinetic characteristics of WE011 for injection in patients with advanced solid tumors; 2) Preliminary evaluation of the anti-tumor efficacy of WE011 for injection in patients with advanced solid tumors. Dose expansion phase: 1) Evaluate the preliminary effectiveness of WE011 for injection in patients with advanced solid tumors; 2) Recommend Phase II dose.

Start Date-

Sponsor / Collaborator

Shanghai Baolong Pharmaceutical Co., Ltd.

100 Clinical Results associated with WE011

Login to view more data

100 Translational Medicine associated with WE011

Login to view more data

100 Patents (Medical) associated with WE011

Login to view more data

100 Deals associated with WE011

Login to view more data